3S3G
Crystal Structure of Human Aldose Reductase Complexed with Tolmetin
Summary for 3S3G
Entry DOI | 10.2210/pdb3s3g/pdb |
Descriptor | Aldose reductase, NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, Tolmetin, ... (4 entities in total) |
Functional Keywords | human aldose reductase, oxidoreductase |
Biological source | Homo sapiens (human) |
Cellular location | Cytoplasm: P15121 |
Total number of polymer chains | 1 |
Total formula weight | 39070.38 |
Authors | |
Primary citation | Zheng, X.,Zhang, L.,Zhai, J.,Chen, Y.,Luo, H.,Hu, X. The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase. Febs Lett., 586:55-59, 2012 Cited by PubMed Abstract: Sulindac (SLD) exhibits both the highest inhibitory activity towards human aldose reductase (AR) among popular non-steroidal anti-inflammatory drugs and clear beneficial clinical effects on Type 2 diabetes. However, the molecular basis for these properties is unclear. Here, we report that SLD and its pharmacologically active/inactive metabolites, SLD sulfide and SLD sulfone, are equally effective as un-competitive inhibitors of AR in vitro. Crystallographic analysis reveals that π-π stacking favored by the distinct scaffold of SLDs is pivotal to their high AR inhibitory activities. These results also suggest that SLD sulfone could be a potent lead compound for AR inhibition in vivo. PubMed: 22155003DOI: 10.1016/j.febslet.2011.11.023 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.8 Å) |
Structure validation
Download full validation report
